Waldenström Macroglobulinemia Market to Gain Momentum During the Forecast Period (2026-2036) Due to Launch of Novel Drug Classes Including BTK Degraders, Non-covalent BTKi, BCL-2 Inhibitors, and Targeted Radiotherapeutics | DelveInsight

Summary

DelveInsight projects steady growth in the Waldenström Macroglobulinemia market through 2036, driven by novel drug classes including BTK degraders, non-covalent BTKi, BCL-2 inhibitors, and targeted radiotherapeutics, alongside improved disease awareness and diagnostics.